-
Company Insights
New![]()
Innovation and Patenting activity of GCC SAB de CV Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of GCC SAB de CV Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Sector Analysis
New![]()
Gulf Cooperation Council (GCC) Destination Tourism Market Insights, Foreign Direct Investment, Source Markets and Opportunities, 2023 Update
Gulf Cooperating Council (GCC) Destination Tourism Insight Report Overview The Gulf Cooperation Council (GCC) is a regional political and economic union comprised of six member states Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates that account for a substantial portion of global crude oil production. The total number of international arrivals in GCC amounted to 49.08 million in 2022. The region garnered a total inbound expenditure of $66.06 billion in 2022. The GCC collectively represents one of...
-
Product Insights
![]()
Amur GCC Blagoveshchensk Complex, Russia
Amur GCC Blagoveshchensk Complex is located in Amur Oblast, Russia. The petrochemicals complex is owned by China Petrochemical Corp (40%); Sibur Holding (60.00. It will be operated by Amur GCC LLC. The project is currently in the planned stage and is expected to start operations in 2026. Amur GCC Blagoveshchensk Complex profile includes core details such as complex name, location, complex status, start year, annual petrochemical capacity (mtpa) for the period 2015-2030, key feedstock, key products produced, operator, technology, key...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CT-080 in Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CT-080 in Colorectal Cancer Drug Details: CT-080 is under development for the treatment of GCC-positive...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CT-080 in Gastric Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CT-080 in Gastric Cancer Drug Details: CT-080 is under development for the treatment of GCC-positive...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CT-080 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CT-080 in Solid Tumor Drug Details: CT-080 is under development for the treatment of GCC-positive...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CT-080 in Esophageal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CT-080 in Esophageal Cancer Drug Details: CT-080 is under development for the treatment of GCC-positive...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Gcc19Cart in Metastatic Colorectal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.GCC19CART in Metastatic Colorectal Cancer Drug Details:Gene therapy is under development for the treatment of relapsed...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vaccine To Target Guanylyl Cyclase C For Oncology in Pancreatic Ductal Adenocarcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vaccine To Target Guanylyl Cyclase C For Oncology in Pancreatic Ductal Adenocarcinoma Drug Details: Ad5-hGCC-PADRE...
-
Product Insights
New![]()
King II Mine
The King II Mine is a coal mine in United States. It is currently in operation. Empower your strategies with our King II Mine report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.